This Collaboration and Exclusive Licensing Agreement expands the Company's existing portfolio of targeted alpha therapies, led by ADVC001, a first-in-class 212Pb-PSMA radioligand therapy. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results